Home > Research > Publications & Outputs > Biological therapy in patients with rheumatoid ...

Links

Text available via DOI:

View graph of relations

Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal: A cross-sectional study

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal: A cross-sectional study. / FERNANDES, Melissa; FIGUEIREDO, Adelaide; OLIVEIRA, Ana Luísa et al.
In: Acta Medica Portuguesa, Vol. 34, No. 5, 31.05.2021, p. 362-371.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

FERNANDES, M, FIGUEIREDO, A, OLIVEIRA, AL, FERREIRA, AC, MENDONÇA, P, TAULAIGO, AV, VICENTE, M, FANICA, MJ, RUANO, C, PANARRA, A, MATEUS, C & MORAES-FONTES, MF 2021, 'Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal: A cross-sectional study', Acta Medica Portuguesa, vol. 34, no. 5, pp. 362-371. https://doi.org/10.20344/AMP.13605

APA

FERNANDES, M., FIGUEIREDO, A., OLIVEIRA, A. L., FERREIRA, A. C., MENDONÇA, P., TAULAIGO, A. V., VICENTE, M., FANICA, M. J., RUANO, C., PANARRA, A., MATEUS, C., & MORAES-FONTES, M. F. (2021). Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal: A cross-sectional study. Acta Medica Portuguesa, 34(5), 362-371. https://doi.org/10.20344/AMP.13605

Vancouver

FERNANDES M, FIGUEIREDO A, OLIVEIRA AL, FERREIRA AC, MENDONÇA P, TAULAIGO AV et al. Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal: A cross-sectional study. Acta Medica Portuguesa. 2021 May 31;34(5):362-371. Epub 2021 Feb 10. doi: 10.20344/AMP.13605

Author

FERNANDES, Melissa ; FIGUEIREDO, Adelaide ; OLIVEIRA, Ana Luísa et al. / Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal : A cross-sectional study. In: Acta Medica Portuguesa. 2021 ; Vol. 34, No. 5. pp. 362-371.

Bibtex

@article{5c7a68ec19ef488bb87122997052cb77,
title = "Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal: A cross-sectional study",
abstract = "Introduction: Clinical outcomes in rheumatoid arthritis have greatly improved with therapeutic advances. Despite the availability of substantial clinical trial evidence, there is a lack of real-life data. The aim of this study was to assess disease status and quality of life in an outpatient population treated with biological disease-modifying anti-rheumatic drugs. Material and Methods: Cross-sectional study recalling all patients ever treated in our unit with biological disease-modifying anti-rheumatic drugs. Clinical and demographic data, compliance, disease activity, functional status, joint deformities, and comorbidities were documented, and patients queried on occupational status, education, marital status and generic health related quality of life questionnaires. Results: Recall was attended by 77 of the original 94 patients. At recall, median age was 63 years old, 82% of the patients were female and the median disease duration was 12 years. Biological therapy was started at a median of four years following disease onset. According to the disease activity score (DAS28), the percentage of patients with high, moderate, low disease activity or remission changed from 50, 45, 0 and 5 (pre-therapy) to 11, 37, 25 and 26 at recall, respectively; functional status was significantly improved. Seventy-five per cent of the patients retained the original treatment with good compliance. Lower Short Form-36 domain scores accompanied a low EQ-5D-3L score. Deceased patients (n = 6) had a lower estimated 10-year survival rate. In this group, biological therapy was discontinued at a higher frequency during follow-up. Discussion: A high disease activity and a high HAQ disability index characterized most patients at pre-bDMARD onset. Conclusion: Despite therapy switches and regular follow-up, a significant percentage of patients still presented with moderate disease activity, functional impairment and a poor health-related quality of life.",
keywords = "Arthritis, Biological Products/therapeutic use, Biological Therapy, Quality of Life, Rheumatoid/drug therapy",
author = "Melissa FERNANDES and Adelaide FIGUEIREDO and OLIVEIRA, {Ana Lu{\'i}sa} and FERREIRA, {Ana Carolina} and Pedro MENDON{\c C}A and TAULAIGO, {Anna V.} and Madalena VICENTE and FANICA, {Maria Jo{\~a}o} and Carina RUANO and Ant{\'o}nio PANARRA and C{\'e}u MATEUS and MORAES-FONTES, {Maria Francisca}",
year = "2021",
month = may,
day = "31",
doi = "10.20344/AMP.13605",
language = "English",
volume = "34",
pages = "362--371",
journal = "Acta Medica Portuguesa",
issn = "0870-399X",
publisher = "CELOM",
number = "5",

}

RIS

TY - JOUR

T1 - Biological therapy in patients with rheumatoid arthritis in a tertiary center in portugal

T2 - A cross-sectional study

AU - FERNANDES, Melissa

AU - FIGUEIREDO, Adelaide

AU - OLIVEIRA, Ana Luísa

AU - FERREIRA, Ana Carolina

AU - MENDONÇA, Pedro

AU - TAULAIGO, Anna V.

AU - VICENTE, Madalena

AU - FANICA, Maria João

AU - RUANO, Carina

AU - PANARRA, António

AU - MATEUS, Céu

AU - MORAES-FONTES, Maria Francisca

PY - 2021/5/31

Y1 - 2021/5/31

N2 - Introduction: Clinical outcomes in rheumatoid arthritis have greatly improved with therapeutic advances. Despite the availability of substantial clinical trial evidence, there is a lack of real-life data. The aim of this study was to assess disease status and quality of life in an outpatient population treated with biological disease-modifying anti-rheumatic drugs. Material and Methods: Cross-sectional study recalling all patients ever treated in our unit with biological disease-modifying anti-rheumatic drugs. Clinical and demographic data, compliance, disease activity, functional status, joint deformities, and comorbidities were documented, and patients queried on occupational status, education, marital status and generic health related quality of life questionnaires. Results: Recall was attended by 77 of the original 94 patients. At recall, median age was 63 years old, 82% of the patients were female and the median disease duration was 12 years. Biological therapy was started at a median of four years following disease onset. According to the disease activity score (DAS28), the percentage of patients with high, moderate, low disease activity or remission changed from 50, 45, 0 and 5 (pre-therapy) to 11, 37, 25 and 26 at recall, respectively; functional status was significantly improved. Seventy-five per cent of the patients retained the original treatment with good compliance. Lower Short Form-36 domain scores accompanied a low EQ-5D-3L score. Deceased patients (n = 6) had a lower estimated 10-year survival rate. In this group, biological therapy was discontinued at a higher frequency during follow-up. Discussion: A high disease activity and a high HAQ disability index characterized most patients at pre-bDMARD onset. Conclusion: Despite therapy switches and regular follow-up, a significant percentage of patients still presented with moderate disease activity, functional impairment and a poor health-related quality of life.

AB - Introduction: Clinical outcomes in rheumatoid arthritis have greatly improved with therapeutic advances. Despite the availability of substantial clinical trial evidence, there is a lack of real-life data. The aim of this study was to assess disease status and quality of life in an outpatient population treated with biological disease-modifying anti-rheumatic drugs. Material and Methods: Cross-sectional study recalling all patients ever treated in our unit with biological disease-modifying anti-rheumatic drugs. Clinical and demographic data, compliance, disease activity, functional status, joint deformities, and comorbidities were documented, and patients queried on occupational status, education, marital status and generic health related quality of life questionnaires. Results: Recall was attended by 77 of the original 94 patients. At recall, median age was 63 years old, 82% of the patients were female and the median disease duration was 12 years. Biological therapy was started at a median of four years following disease onset. According to the disease activity score (DAS28), the percentage of patients with high, moderate, low disease activity or remission changed from 50, 45, 0 and 5 (pre-therapy) to 11, 37, 25 and 26 at recall, respectively; functional status was significantly improved. Seventy-five per cent of the patients retained the original treatment with good compliance. Lower Short Form-36 domain scores accompanied a low EQ-5D-3L score. Deceased patients (n = 6) had a lower estimated 10-year survival rate. In this group, biological therapy was discontinued at a higher frequency during follow-up. Discussion: A high disease activity and a high HAQ disability index characterized most patients at pre-bDMARD onset. Conclusion: Despite therapy switches and regular follow-up, a significant percentage of patients still presented with moderate disease activity, functional impairment and a poor health-related quality of life.

KW - Arthritis

KW - Biological Products/therapeutic use

KW - Biological Therapy

KW - Quality of Life

KW - Rheumatoid/drug therapy

U2 - 10.20344/AMP.13605

DO - 10.20344/AMP.13605

M3 - Journal article

C2 - 33566755

AN - SCOPUS:85102046671

VL - 34

SP - 362

EP - 371

JO - Acta Medica Portuguesa

JF - Acta Medica Portuguesa

SN - 0870-399X

IS - 5

ER -